Is iron maintenance therapy better than load and hold?

Editorial

Connie M Rhee et al. J Am Soc Nephrol. 2013 Jun.

. 2013 Jun;24(7):1028-31.

doi: 10.1681/ASN.2013050456. Epub 2013 Jun 20.

No abstract available

Conflict of interest statement

Potential Conflicts of Interest:

Dr. Kalantar has served as a consultant to Amgen, DaVita, Fresenius, Keryx, and Vifor.

The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients.
Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA. Kshirsagar AV, et al. Am J Med. 2013 Jun;126(6):541.e1-541.e14. doi: 10.1016/j.amjmed.2012.11.030. Epub 2013 Apr 15. Am J Med. 2013. PMID: 23597800 Free PMC article.

1. Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR. Intravenous iron versus erythropoiesis-stimulating agents: Friends or foes in treating chronic kidney disease anemia? Adv Chronic Kidney Dis. 2009;16:143–151. - PubMed
1. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease? Clin J Am Soc Neph. 2006;1(supplement):S9–S18. - PubMed
1. Murray MJ, Murray AB, Murray MB, Murray CJ. The adverse effect of iron repletion on the course of certain infections. Br Med J. 1978;2:1113–1115. - PMC - PubMed
1. Waterlot Y, Cantinieaux B, Hariga-Muller C, De Maertelaere-Laurent E, Vanherweghem JL, Fondu P. Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: The critical role of iron overload. Br Med J (Clin Res Ed) 1985;291:501–504. - PMC - PubMed
1. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002;40:90–103. - PubMed